WoodTrust Financial Corp Makes New Investment in IDEXX Laboratories, Inc. $IDXX

Key Points

• WoodTrust Financial Corp has acquired a new position in IDEXX Laboratories, purchasing 12,619 shares valued at approximately $6.77 million during the second quarter.
• Institutional investors now own 87.84% of IDEXX Laboratories' stock, with several firms increasing their stake, including Sax Wealth Advisors and Shell Asset Management.
• IDEXX Laboratories announced a strong earnings report, with earnings per share (EPS) of $3.63, beating estimates and showing a revenue increase of 10.6% year-over-year.

WoodTrust Financial Corp acquired a new position in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX - Free Report) in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor acquired 12,619 shares of the company's stock, valued at approximately $6,768,000.

Several other institutional investors and hedge funds have also recently bought and sold shares of the business. Sax Wealth Advisors LLC increased its position in IDEXX Laboratories by 11.5% during the 2nd quarter. Sax Wealth Advisors LLC now owns 1,528 shares of the company's stock worth $820,000 after buying an additional 158 shares during the period. Venturi Wealth Management LLC acquired a new stake in shares of IDEXX Laboratories during the 2nd quarter valued at $630,000. Shell Asset Management Co. boosted its holdings in shares of IDEXX Laboratories by 122.6% during the 2nd quarter. Shell Asset Management Co. now owns 3,777 shares of the company's stock valued at $2,026,000 after acquiring an additional 2,080 shares in the last quarter. HTG Investment Advisors Inc. acquired a new position in IDEXX Laboratories during the 2nd quarter worth about $217,000. Finally, KLP Kapitalforvaltning AS lifted its holdings in IDEXX Laboratories by 3.1% during the 2nd quarter. KLP Kapitalforvaltning AS now owns 39,600 shares of the company's stock worth $21,239,000 after buying an additional 1,200 shares during the period. Institutional investors own 87.84% of the company's stock.

Analysts Set New Price Targets

IDXX has been the subject of a number of research analyst reports. Jefferies Financial Group initiated coverage on IDEXX Laboratories in a research report on Tuesday, July 1st. They issued a "buy" rating and a $625.00 target price for the company. Leerink Partners boosted their target price on IDEXX Laboratories from $580.00 to $600.00 and gave the stock an "outperform" rating in a research note on Thursday, July 17th. JPMorgan Chase & Co. upped their price objective on IDEXX Laboratories from $550.00 to $675.00 and gave the company an "overweight" rating in a research note on Monday, August 4th. UBS Group started coverage on shares of IDEXX Laboratories in a report on Wednesday, October 1st. They issued a "neutral" rating and a $720.00 price target on the stock. Finally, BTIG Research upped their price target on shares of IDEXX Laboratories from $545.00 to $785.00 and gave the company a "buy" rating in a research report on Tuesday, August 5th. One analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating and four have given a Hold rating to the company's stock. According to data from MarketBeat.com, IDEXX Laboratories has an average rating of "Moderate Buy" and an average target price of $656.50.

Insider Activity at IDEXX Laboratories

In other IDEXX Laboratories news, EVP Michael Lane sold 8,411 shares of IDEXX Laboratories stock in a transaction on Wednesday, August 6th. The shares were sold at an average price of $627.74, for a total value of $5,279,921.14. Following the completion of the transaction, the executive vice president owned 7,132 shares of the company's stock, valued at approximately $4,477,041.68. The trade was a 54.11% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director M Anne Szostak sold 2,187 shares of IDEXX Laboratories stock in a transaction on Friday, August 22nd. The shares were sold at an average price of $647.33, for a total transaction of $1,415,710.71. Following the completion of the transaction, the director directly owned 262 shares of the company's stock, valued at $169,600.46. The trade was a 89.30% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 54,057 shares of company stock valued at $34,293,468 over the last three months. Company insiders own 0.98% of the company's stock.

IDEXX Laboratories Stock Down 0.1%

Shares of IDXX stock opened at $627.28 on Wednesday. The company has a debt-to-equity ratio of 0.31, a current ratio of 1.11 and a quick ratio of 0.79. The company has a market capitalization of $50.18 billion, a price-to-earnings ratio of 52.23, a PEG ratio of 4.07 and a beta of 1.58. The company's fifty day moving average price is $636.83 and its 200-day moving average price is $538.44. IDEXX Laboratories, Inc. has a one year low of $356.14 and a one year high of $688.12.

IDEXX Laboratories (NASDAQ:IDXX - Get Free Report) last announced its earnings results on Monday, August 4th. The company reported $3.63 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.28 by $0.35. The firm had revenue of $1.11 billion for the quarter, compared to analysts' expectations of $1.06 billion. IDEXX Laboratories had a net margin of 24.41% and a return on equity of 64.42%. The business's revenue was up 10.6% compared to the same quarter last year. During the same period in the prior year, the company earned $2.44 EPS. IDEXX Laboratories has set its FY 2025 guidance at 12.400-12.760 EPS. Sell-side analysts expect that IDEXX Laboratories, Inc. will post 11.93 EPS for the current fiscal year.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.

Want to see what other hedge funds are holding IDXX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for IDEXX Laboratories, Inc. (NASDAQ:IDXX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.